Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GS-5745 in Rheumatoid Arthritis
NCT02176876Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- Aug 2014
- Primary completion
- Apr 2015
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in rheumatoid arthritis (RA) comparing GS-5745 with Placebo (2 arms). Primary endpoint: Incidence of adverse events, changes in laboratory tests and vital signs from baseline, and development of immunogenicity after dosing up to 100 days. Started Aug 2014; status: completed.
02
Drugs
andecaliximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02176876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02176876.